|
Genitope Corporation - Company Profile Snapshot
| Company Profile: |
Genitope Corporation |
| Ticker: |
GTOP |
| Exchanges: |
OTC |
| 2007 Sales: |
n/a |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Medical Services |
| Country: |
UNITED STATES |
| Employees: |
206 |
Business Description
Genitope Corporation. The Group's principal activities are to research and develop immunotherapies for the treatment of cancer. Immunotherapies are treatments that utilize the immune system to combat diseases. The Group's product, MyVax personalized immunotherapy, is a patient-specific active immunotherapy that is based on the genetic makeup of a patient's tumor and is designed to activate a patient's immune system to identify and attack cancer cells. The MyVax is currently in a pivotal Phase 3 clinical trial and additional Phase 2 clinical trials for the treatment of B-cell non-Hodgkin's lymphoma. The Group's Phase III clinical trial is for the treatment of follicular B-cell NHL. The Group is also developing MyVax for the treatment of chronic lymphocytic leukemia (CLL). The Group operates in the domestic market.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
